Zydus Lifesciences: Zydus launches anti-cancer generic drug olaparib in India
Zydus Lifesciences on Wednesday said it has launched olaparib, a PARP inhibitor, under the brand name IBYRA in India, making ...
Zydus Lifesciences on Wednesday said it has launched olaparib, a PARP inhibitor, under the brand name IBYRA in India, making ...
Barcelona: An investigation conducted by the UAB's Institut de Neurociencies (INc-UAB) showed the advantages of vorinostat in animal models following ...
Glenmark on Tuesday announced the launch of an alliance with its clinical stage-biotech subsidiary Ichnos Sciences to accelerate new drug ...
New Delhi : An anti-cancer jab that can cut down treatment time for some by three quarters has been rolled ...
Aurobindo Pharma on Friday said its wholly-owned arm, Eugia Pharma Specialities Ltd has entered into a voluntary sub-licensing agreement with ...
Mumbai: Scientists from Mumbai's Tata Institute of Fundamental Research (TIFR), the Agharkar Research Institute (ARI) in Pune, and IIT Hyderabad ...
NEW DELHI: Several anti-cancer drugs, antibiotics and vaccines will now become more affordable as they are among 34 new additions ...
Dr Reddy's Laboratories on Saturday said it has inked a pact with US-based Citius Pharmaceuticals to sell its rights to ...
Copyright © 2021 Asia Post.
Asia Post is not responsible for the content of external sites.